☆ 4.5 Article

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

BREAST CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients

Leonora W. de Boo et al.

Summary: This study evaluated the BRCA1-like DNA copy number signature as a predictive biomarker for capecitabine benefit in the TNBC subgroup. The results showed that addition of capecitabine improved recurrence-free survival in non-BRCA1-like tumor patients. Patients with BRCA1-like TNBC may also benefit from the addition of capecitabine.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

P. Schmid et al.

Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Meeting Abstract Oncology

Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance

Anton Safonov et al.

CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

C. E. Geyer et al.

Summary: The OlympiA trial demonstrated that adjuvant therapy with the oral PARP inhibitor, olaparib, significantly improves overall survival in patients with gBRCA1/2pv-associated early breast cancer. The study also showed improvements in invasive disease-free survival and distant disease-free survival, with no new safety issues identified.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Cyclin-Dependent Kinase 4/6=Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes

Luisina Bruno et al.

Summary: The study retrospectively examined the efficacy of CDK 4/6 inhibitors combined with endocrine therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Patients with pathogenic gene variants had worse outcomes.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

N. Harbeck et al.

Summary: Adjuvant abemaciclib combined with endocrine therapy significantly improved invasive disease-free survival in patients with early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic but did not affect the benefits of abemaciclib. The robust treatment benefit of abemaciclib extended beyond the planned 2-year treatment period.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2-advanced breast cancer: MONARCH 2 & 3 trials

Masakazu Toi et al.

Summary: In East Asian patients with HR+, HER2- advanced breast cancer, abemaciclib in combination with ET demonstrated significantly prolonged progression-free survival, with generally tolerable safety profiles. Pharmacokinetics were similar between East Asians and non-East Asians in both MONARCH 2 and MONARCH 3 trials.

CANCER SCIENCE (2021)

添加到收藏夹

Review Oncology

An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer

Yen-Shen Lu et al.

Summary: Breast cancer burden among Asians is around 40% of the global burden. While most therapies show comparable efficacy and safety in Asian and non-Asian patients, differences due to pharmacogenetic variations exist. Asian patients have a higher incidence of hematological toxicities, such as neutropenia, but dose adjustments can effectively manage adverse events.

TARGETED ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?

Ji-Yeon Kim et al.

Summary: This study identified several factors associated with primary resistance to palbociclib in combination with endocrine therapy in HR+, HER2-MBC patients, and developed a prediction model to help inform first-line treatment strategies. Further well-designed clinical trials are needed to validate the predictive model.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Ingrid A. Mayer et al.

Summary: The study showed that adjuvant platinum agents do not improve outcomes in patients with residual invasive disease (RD) of basal subtype TNBC post- NAC, and are associated with more severe toxicity compared with capecitabine. Participants had a lower than expected 3-year invasive disease-free survival (iDFS) regardless of study treatment, highlighting the need for better therapies in this high-risk population.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt et al.

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Y. H. Park et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Ana Lluch et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

Tatsunori Shimoi et al.

BREAST CANCER (2020)

添加到收藏夹

Meeting Abstract Oncology

KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)

R. Dent et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

Xiao Xia Guo et al.

CANCER MANAGEMENT AND RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Mark Robson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

N. Masuda et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

Elizabeth A. Mittendorf et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system

Clifford A. Hudis et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Multidisciplinary Sciences

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

HE Bryant et al.

NATURE (2005)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

H Farmer et al.

NATURE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.